bioAffinity Technologies (BIAF) Other Accumulated Expenses (2021 - 2026)

bioAffinity Technologies has disclosed Other Accumulated Expenses across 6 years of filings, most recently posting $23630.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 46.54% year-over-year to $23630.0; the TTM figure through Mar 2026 stood at $23630.0 (down 46.54% YoY), while the FY2025 annual figure was $24138.0, down 59.79% from the prior year.
• Other Accumulated Expenses fell to $23630.0 in Q1 2026, from $24138.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for BIAF reached as high as $112590.0 in Q2 2025 and fell as low as $1751.0 in Q2 2024.
• The 5-year median for Other Accumulated Expenses is $21564.0 (2023), against an average of $28286.6.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses tumbled 64.98% — and 2025, when it surged 6330.04%.
• A 5-year view of Other Accumulated Expenses shows it stood at $5852.0 in 2022, then soared by 233.19% to $19498.0 in 2023, then surged by 207.9% to $60035.0 in 2024, then sank by 59.79% to $24138.0 in 2025, then fell by 2.1% to $23630.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $23630.0, $24138.0, and $28658.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.